A prospective study of Trimethoprime-sulfamethoxazole(TMP/SMX) for prevention of Pneumocystis pneumonia(PCP) in patients under immunosuppressive therapy
Not Applicable
- Conditions
- The patients with rheumatic diseases who are receiving more than 30mg/day of prednisolone
- Registration Number
- JPRN-UMIN000001647
- Lead Sponsor
- Division of Rheumatology,Department of Internal Medicine,Toho University School of Mdicine,Tokyo,Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1.On TMP/SMX 2.Suffering from PCP 3.Complicated with serious liver and/or renal disfunction,cytopenia 4.Allergy to TMP/SMX 5.Pregnant,and/or nursing 6.In approppriate patients decided by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of PCP
- Secondary Outcome Measures
Name Time Method 1)Positive rate of Pneumocystis polymerase chain reaction in sputum 2)Incidence of the increased plasma level of beta-D-gulucan